)
10X Genomics (TXG) investor relations material
10X Genomics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Financial performance and recent results
Achieved $599 million in 2025 revenue and $166 million in Q4, surpassing guidance, with year-end cash balance exceeding $520 million and over $100 million cash growth from 2024.
Q4 growth was driven by both instruments and consumables, with CapEx growing nearly 30% sequentially and Chromium consumables reactions up more than 20%.
Chromium instrument placements reached over 6,400 cumulatively, with 1,500 spatial instruments sold by end of 2025; instrument demand remains challenged by tight capital budgets.
Spatial consumables and the Flex assay saw strong momentum, with Flex becoming the most popular assay by volume last quarter.
Plan to reinstate full-year guidance during the Q4 call, barring unforeseen circumstances.
Product innovation and platform development
Operates three category-defining platforms, launching over 35 major products in the last decade and maintaining the largest ecosystem of users and publications.
Chromium leads in single cell analysis, with Flex assay offering sensitivity, flexibility, and cost-effectiveness.
Spatial platforms Visium and Xenium enable comprehensive molecular, cellular, and tissue analysis; Xenium is now the primary growth engine in spatial.
Multi-omics capabilities introduced with Xenium RNA and protein panel, receiving strong initial feedback for practical, scalable workflows.
Acquired Scale Biosciences to enhance experiment scale and integrate new technologies into the Chromium portfolio.
AI and virtual cell initiatives
Integrates large-scale biological data with AI models to accelerate understanding and medicine development.
Supports development of virtual cell foundation models, collaborating with leading academic and industry partners.
Provides massive, high-quality datasets essential for training AI models in therapeutic discovery.
Announced partnership with Cancer Research Institute to build a Discovery Engine dataset for immunotherapy and a high-resolution immune atlas.
AI partnerships, such as with Anthropic, aim to address data analysis bottlenecks and further integrate AI into research workflows.
- TimeTickerHeadlineOpen
- 323410
Strong growth in customers, profits, and deposits, with stable asset quality and global milestones. - 3407
Net income rose 22.7% year-over-year, with improved financials and a revised upward forecast. - RYM
Refreshed strategy targets NZD 150m cash flow uplift, NZD 500m cash release, and resumed dividends by FY 2028. - 9101
Profits fell across most segments, but energy shipping and a major acquisition stood out. - 4626
Double-digit profit and sales growth, with strong segment results and a stock split impact. - 2371
Revenue up 21.5% YoY, but profit down on higher investments; LiPLUS Holdings acquired. - 3401
Major impairments and divestitures led to a net loss and lower revenue across all segments. - 8002
Profit forecast raised to ¥540.0B and annual dividend to ¥107.50 per share after strong results. - COF
Profit rebounded, NTA and occupancy rose, with strong leasing and premium divestment. - NUF
Statutory loss reported, seeds business repositioned, new CEO appointed, all resolutions passed.
Next 10X Genomics earnings date
Next 10X Genomics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage